NCT01621568View on ClinicalTrials.gov

Sunitinib for Advanced Thymus Cancer Following Earlier Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 15, 2012

Primary Completion Date

April 30, 2021

Study Completion Date

July 31, 2024

Conditions
ThymomaThymus Neoplasms
Interventions
DRUG

Sunitinib

50mg/day for 4 weeks daily, by mouth with 2 weeks off (6 week cycle)

DRUG

Sunitinib

50mg/day for 2 weeks daily, by mouth with 1 week off (3 week cycle)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

Indiana University School of Medicine

OTHER

lead

National Cancer Institute (NCI)

NIH

NCT01621568 - Sunitinib for Advanced Thymus Cancer Following Earlier Treatment | Biotech Hunter | Biotech Hunter